Background: The impact of dupilumab, an antieinterleukin (IL) 4 receptor a antibody that inhibits IL-4 and IL-13 signaling, on vaccine responses of patients with atopic dermatitis (AD) is unknown.
Results: In total, 178 patients completed the study. Similar positive immune responses ($4-fold increase in antibody titer, or an antibody titer of $8) were achieved in the dupilumab and placebo groups to tetanus (83.3% and 83.7%, respectively) and meningococcal polysaccharide (86.7% and 87.0%, respectively). Dupilumab significantly decreased total serum IgE; most dupilumab-treated patients were Tdap-IgE seronegative at week 32 (62.2% dupilumab and 34.8% placebo). Dupilumab improved key AD efficacy endpoints (P \ .001). Injection-site reactions and conjunctivitis were more common with dupilumab; AD exacerbations more frequent with placebo.
Limitation: Patients' prior vaccination status was not available before enrollment.
Conclusion:
Dupilumab did not affect responses to the vaccines studied, significantly decreased IgE, and improved measures of AD severity versus placebo, with an acceptable safety profile. ( J Am Acad Dermatol 2019;80:158-67.)
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Atopic dermatitis (AD), a chronic inflammatory skin disease, affects #20% of children and 10% of adults. [1] [2] [3] [4] Immune dysregulation and skin-barrier dysfunction play key roles in AD pathogenesis. [5] [6] [7] Immune abnormalities include cutaneous T-cell expansion and elevated expression of type 2 cytokines, interleukin (IL) 4 and IL-13, central drivers of type 2 inflammatory diseases, such as AD, asthma, chronic sinusitis with nasal polyposis, and eosinophilic esophagitis. [8] [9] [10] [11] Dupilumab, a fully human, VelocImmune-derived monoclonal antibody directed against the IL-4 receptor a subunit, inhibits signaling of both IL-4 and IL-13. 8, 9, [11] [12] [13] Dupilumab has been shown to significantly improve signs and symptoms of moderate-to-severe AD, 8, [14] [15] [16] [17] [18] asthma, 9,19-21 chronic sinusitis with nasal polyposis, 22 and eosinophilic esophagitis 23 and is approved in the European Union, United States, and Japan as well as other countries for the treatment of adults with inadequately controlled moderate-to-severe AD. Although multiple immune responses interact to provide vaccine protection, antibody titers are often surrogates or correlates of vaccine-induced immunity. 24 T-celledependent vaccines elicit the production of functional IgG antibodies through T-cell activation; T-celleindependent vaccines result in IgM responses by B-cell activation independent of T cells. 25 Vaccination might cause IgE-mediated hypersensitivity and other immediate-type allergic reactions. 26 The type 2eskewed cytokine milieu of AD patients has been linked to vaccine hyporesponsiveness during infancy 27, 28 ; it is unclear whether therapeutic modulation affects vaccine responses. 29 Severe AD is associated with increased vaccine-specific IgE responses, with a risk for adverse events during subsequent antigen exposure. 30 As dupilumab suppresses IL-4 and IL-13 signaling, there is a need to assess immune responses to vaccination in patients receiving this drug. Here, we report results from a study examining whether dupilumab affects antibody responses to 2 commonly administered vaccines in adults with moderate-to-severe AD and examines dupilumab efficacy and safety.
METHODS

Study design
This investigation was a phase 2, randomized, double-blinded, multicenter, placebo-controlled, parallel-group study conducted in the United States (August 2014-September 2015; LIBERTY AD EVALUATE; ClinicalTrials.gov identifier: NCT02210780). Patients were randomized (1:1) via an interactive response technology system to subcutaneous dupilumab or placebo weekly for 16 weeks. At week 12, patients received 1 dose each of tetanus toxoid with reduced diphtheria toxoid and acellular pertussis vaccine (Tdap), and quadrivalent meningococcal polysaccharide vaccine (MPSV4).
CAPSULE SUMMARY d
The type 2eskewed cytokine milieu in atopic dermatitis has been linked to vaccination-hyporesponsiveness in infancy. 33 ) were administered intramuscularly in the deltoid muscle and subcutaneously in the opposite arm, respectively, at week 12; both were nonlive vaccines. Concomitant AD therapies (TCI, TCS [#10 mg prednisone or equivalent], or both) were permitted. Rescue treatment (TCS of higher potency than at baseline, TCI, high-dose systemic corticosteroids) was permitted for intolerable AD symptoms (prohibited concomitant medications and procedures materials available from the authors upon request).
Endpoints
Primary endpoint was proportion of patients with a positive response to the tetanus component of Tdap at week 16, defined as $4-fold increase from baseline anti-tetanus IgG concentration in patients with prevaccination tetanus antibody concentrations $0.1 or $0.2 IU/mL in patients with prevaccination tetanus antibody concentrations \0.1 IU/mL. 34 Secondary endpoints were proportions of patients at week 16 with a) a positive response to tetanus toxoid ($2-fold increase from baseline anti-tetanus IgG concentration in patients with prevaccination tetanus antibody concentrations $0.1 IU/mL or $0.2 IU/mL in patients with prevaccination concentrations of \0.1 IU/mL); b) a positive response to MPSV4 (meningococcal serogroup C serum bactericidal assay [SBA] titer $8) 35 ; c) an IGA score of 0 or 1; d) an $50% reduction in EASI (EASI-50); and e) an $75% reduction in EASI (EASI-75). Other secondary endpoints were changes from baseline at week 16 in peak pruritus Numerical Rating Scale, body surface area, erythema, infiltration and papulation, excoriations, lichenification of Global Individual Sign Score, and Patient-Oriented Eczema Measure (prespecified endpoints available from the authors upon request). Total IgE levels and proportions of patients who were tetanus-antigenespecific and pertussis-antigenespecific IgE seropositive at weeks 12, 16, and 32 were analyzed post-hoc.
Tetanus toxoid-specific IgG antibodies and meningococcal serogroup C SBA titers
Tetanus toxoidespecific IgG antibodies were measured using VaccZyme Anti-Tetanus Enzyme Immunoassay (Binding Site Group, Birmingham, UK). The quantitative sandwich enzyme immunoassay was performed by Covance Central Laboratory Services (Indianapolis, IN). The baby rabbit complement meningococcal SBA assay was performed by the Vaccine Evaluation Unit of Public Health England (Manchester, UK) using a validated method, and SBA titers were expressed as the reciprocal of the final dilution providing $50% killing compared with the number of colonyforming units at 60 minutes. Baseline was day 1, and week 12 measurements (not shown) were collected to ensure that no patient received vaccination between baseline and week 12.
Antigen-specific IgE A low abundance of serum antigenespecific IgE meant a modified, multiplexed Luminex assay (Luminex Corporation, Austin, TX) was employed to measure tetanus and acellular pertussis antigenespecific IgE responses. 36 Sera were treated with GullSORB (Meridian Bioscience Inc, Cincinnati, OH) to remove potentially competing IgG and incubated with purified pertussis toxin mutant, pertactin, or tetanus toxoid (all from List Biological Laboratory, Campbell, CA) coupled to fluorescentbarcoded MagPlex microspheres (Luminex Corporation). The beads were washed, and bound J AM ACAD DERMATOL VOLUME 80, NUMBER 1 IgE was detected via anti-IgEephycoerythrin antibody (Clone BE5, Thermo Fisher Scientific, Waltham, MA). Samples were analyzed on a Luminex FLEXMAP 3D instrument, and pertussis toxin mutant, pertactin, or tetanus toxoid IgEepositive beads were reported as mean fluorescent intensities. The detection limit was defined as 3 standard deviations above the mean fluorescent intensity of a negative control serum. Total serum IgE was measured by ImmunoCAP Fluorescent Enzyme Immunoassay (Thermo Scientific, Phadia AB, Uppsala, Sweden).
Safety
Safety was assessed through week 32 (incidence of treatment-emergent adverse events [TEAEs] and serious TEAEs) coded per Medical Dictionary for Regulatory Activities, v18.0. The investigator (or designee) recorded all adverse events that occurred from the signing of informed consent until study end. Information about injection-site reactions was recorded by site staff or patient, if occurring outside the clinic.
Statistics
All categorical variables, including vaccine-related endpoints and efficacy analyses, were analyzed using a CochraneManteleHaenszel test stratified by randomization strata (moderate [IGA 3] vs severe [IGA 4]). Analyses included all randomized patients who received any study drug or vaccine injection and had measured responses to the tetanus toxoid vaccine. Patients who had missing values at or withdrew before week 16 were defined as nonresponders. For efficacy analyses, patients who received rescue treatment were defined as nonresponders from that timepoint onwards.
Nominal P values were derived from the CochraneManteleHaenszel test stratified by randomization strata.
Continuous dupilumab efficacy variables were analyzed using a mixed-effect model repeatedmeasure approach. Efficacy data were set to missing after rescue treatment was used or a patient discontinued. Analysis of the IgE endpoints included all treated patients at weeks 0, 12, 16, and 32; patients with missing values were excluded. Vaccine titers at weeks 0, 12, and 16 and total IgE levels between visits in both treatment groups were analyzed using Friedman test adjusted for multiple comparisons. Percentage change of total IgE levels from baseline to week 32 between treatment groups was analyzed by a ManneWhitney U test. Tdap-specific IgE seropositivity was a categorical variable and was analyzed by Fisher's exact test. Values are means 6 SD unless otherwise specified. AD, Atopic dermatitis; BSA, body surface area; EASI, Eczema Area and Severity Index; GISS, Global Individual Signs Score; IGA, Investigator's Global Assessment; NRS, Numerical Rating Scale; POEM, Patient-Oriented Eczema Measure; Q1, first quartile; Q3, third quartile; SD, standard deviation.
RESULTS
Patients
Of 243 patients screened, 194 were enrolled and randomized, and 178 (91.8%) completed the study (Fig 1) . Patient demographics and baseline disease characteristics were similar in both groups (Table I) . During the study, most patients used concomitant TCS: 66.0% and 73.3% in dupilumab and placebo groups, respectively. Overall, 9.8% of patients received rescue treatment for intolerable AD symptoms: 15.5% and 4.1% for placebo and dupilumab, respectively, indicating better control of AD symptoms in the dupilumab group.
Immune responses to vaccinations
Similar proportions of patients had positive responses ($4-fold increase in titer) to tetanus vaccination at week 16 (primary endpoint): dupilumab 83.3% and placebo 83.7% (90% confidence interval [CI] of difference, dupilumab vs placebo À9.41 to 8.69). The proportions of patients achieving antitetanus IgG responses ($2-fold increase) at week 16 (secondary endpoint) were also similar: dupilumab 95.6% and placebo 94.6% (90% CI difference, dupilumab vs placebo À4.29 to 6.27). No differences were observed at baseline, week 12, or week 16 with tetanus toxoid titers between treatment groups (P[.9999, all comparisons; Fig 2, A) . Overall median tetanus toxoid titers significantly increased in both groups at week 16 versus weeks 0 and 12 (P \.0001; placebo week 0 = 1.12 IU/mL, week 12 = 1.11 IU/mL, and week 16 = 15.25 IU/mL; dupilumab week 0 = 1.09 IU/mL, week 12 = 1.21 IU/mL, and week 16 = 13.91 IU/mL; Fig 2, A) .
Similar proportions of patients had a positive response to serotype C of the meningococcal polysaccharide vaccine at week 16: dupilumab 86.7% and placebo 87.0% groups (90% CI difference, dupilumab vs placebo À8.54 to 7.96). No differences were observed for SBA titers between treatment groups (P [ .9999 for all comparisons; Fig 2, B) , but both groups had significantly increased median SBA titers at week 16 versus weeks 0 and 12 (P \ .0001; placebo week 0 = \4 IU/mL, week 12 = \4 IU/mL, and week 16 = 1024 IU/mL; dupilumab week 0 = \4 IU/mL, week 12 =\4 IU/mL, and week 16 = 1024 IU/ mL; Fig 2, B) . J AM ACAD DERMATOL VOLUME 80, NUMBER 1
Vaccine-specific IgE
Samples from weeks 12 (baseline vaccine administration), 16, and 32 were available for antigenspecific IgE analyses. Dupilumab-treated patients were less likely to develop Tdap-specific IgE (pertussis toxin, pertactin, and tetanus toxoid antigens) by week 32: dupilumab 37.8% and placebo 65.2% (P = .001) (Table II) .
Changes in total IgE concentrations
Placebo-treated patients showed no changes in median total IgE levels (Fig 3, A) (Fig 3, B) . At week 32, the median percent decrease in total IgE from baseline was À57% in the dupilumab group and À7.3% in the placebo group (Fig 3, C ) .
Dupilumab efficacy
Dupilumab demonstrated clinically and statistically significant improvements in all AD efficacy measures. The IGA score of 0/1 at week 16 was 44.3% for dupilumab and 10.3% for placebo (Table  III) ; significantly more patients with dupilumab than placebo attained EASI-50 (72.2% vs 32.0%, respectively) or EASI-75 (53.6% vs 19.6%, respectively) (Table III) . Dupilumab-treated patients had significantly greater improvements in peak pruritus Numerical Rating Scale and experienced significantly greater reductions in percent body surface area affected by AD, Global Individual Sign Score components, and Patient-Oriented Eczema Measure scores in comparison with placebo-treated patients (Supplemental Table I ; available at http://www.jaad. org).
Safety
TEAE rates were similar between groups (Table  IV) ; 55.7% of patients in the dupilumab group and 61.9% in the placebo reported $1 TEAE; most were mild or moderate. No deaths were reported. Three patients in the dupilumab group reported 3 different serious TEAEs: mycosis fungoides stage IV (ongoing at study end), squamous cell carcinoma of the skin (resolved without sequelae), and serum sicknesslike reaction (resolved without sequelae); only the latter was considered treatment-related. No serious TEAEs were reported in the placebo group. The following TEAEs led to the withdrawal of 5 patients on dupilumab: mycosis fungoides, serum sicknesslike reaction, a photosensitivity reaction, dizziness and fatigue, and conjunctivitis of moderate severity. There were no withdrawals due to TEAEs in the placebo group. Upper respiratory tract infection was the most frequently reported TEAE in both groups, and they occurred at similar rates. Conjunctivitis and injection-site reactions to dupilumab or placebo were mild or moderate and more frequent with dupilumab than placebo. AD exacerbations and nonherpetic skin infections occurred more frequently with placebo than dupilumab (Table  IV) . Injection-site reactions to Tdap occurred only in the placebo group (3.1%); there were no injectionsite reactions to MPSV4.
DISCUSSION
Vaccine immune responses to tetanus toxoid and meningococcal serogroup C met established correlates of vaccine-induced immunity with an acceptable safety profile in adult patients with moderate-to-severe AD treated with dupilumab 300 mg weekly and were robust and comparable in patients receiving dupilumab or placebo. Dupilumab also reduced vaccine-specific IgE and total IgE levels in comparison with placebo. Vaccination after 12-week dupilumab therapy was not associated with any adverse clinical effects. Dupilumab also improved multiple AD efficacy measures in comparison with placebo, consistent with previous phase 1-3 studies. 8, [14] [15] [16] [17] [18] Concomitant TCS use did not affect vaccine immune responses.
Humoral responses to T-celledependent vaccines normally require successful presentation of antigen via T-cell receptors, production of T-cell and antigen-presenting cell cytokines, and celldependent costimulatory signaling to produce antigen-specific antibodies. 25 For vaccine responses to tetanus toxoid, IgG production is T-cell dependent. [37] [38] [39] Because dupilumab acts on IL-4 and IL-13, both type 2 cytokines, dupilumab was not expected to affect total tetanus toxoid IgG levels, as observed here. Achievement of the primary endpoint was consistent with a randomized clinical trial of healthy adults receiving Tdap vaccination, 40 and titer levels at every timepoint evaluated were similar to placebo, demonstrating that dupilumab does not impair tetanus vaccine response. In contrast with the tetanus vaccine, polysaccharide vaccines, such as MPSV4, are thought to elicit T-celleindependent immune responses. 26 In this study, the proportions of patients attaining SBA titers $8 after vaccination with MPSV4 and the overall SBA titers at each timepoint were similar in the dupilumab and placebo groups, indicating that dupilumab has no adverse effects on immune responses elicited by T-celleindependent vaccines. Given the effect of dupilumab on type 2 cytokines, it is possible that treatment with dupilumab shifts type 2eskewed vaccines in a type 1 direction, not by increasing total IgG production, but by changing the IgG subtypes from IgG4 (type 2) to IgG1 (type 1), thereby potentially improving the functional response to vaccines. The reduction in vaccine-specific IgE responses is consistent with the mechanism of action of dupilumab and with other reports showing reduced total and allergen-specific IgE after dupilumab treatment. 8, 22, 41 Patients with severe AD have an increased vaccine-specific IgE immune response, which might be associated with their increased risk for adverse events during future vaccination or antigen exposure 30 ; additional studies are needed to determine whether dupilumab reduces the risk for subsequent adverse events by limiting vaccinespecific IgE responses.
Dupilumab had an acceptable safety profile, with injection-site reactions and conjunctivitis occurring more often with dupilumab and nonherpetic skin infections occurring more frequently with placebo, similar to previous dupilumab AD trials. [16] [17] [18] Study limitations are that prior vaccination status was not available before enrollment and that permitted, but not mandatory, TCS use limits comparison of efficacy data with phase 3 studies, 16 despite comparable design and outcomes with the LIBERTY AD CHRONOS trial. 17 In conclusion, in adults with moderate-to-severe AD, vaccination during dupilumab treatment did not affect IgG production or functional responses. Dupilumab led to lower levels of vaccine-specific IgE and total IgE than placebo. Vaccination did not affect dupilumab efficacy or safety. Vaccination with T-celledependent and T-celleindependent vaccines in dupilumab-treated patients is effective with an acceptable safety profile. These findings are important for the general practicing dermatologist as they demonstrate that nonlive vaccines such as Tdap and MPSV4 can be indicated safely and are immunogenic in adult patients with moderate-to-severe AD treated with dupilumab.
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